6AZU
Holo IDO1 crystal structure
6AZU の概要
エントリーDOI | 10.2210/pdb6azu/pdb |
分子名称 | Indoleamine 2,3-dioxygenase 1, PROTOPORPHYRIN IX CONTAINING FE, SULFATE ION (3 entities in total) |
機能のキーワード | holoenzyme ido1, oxidoreductase |
由来する生物種 | Homo sapiens (Human) |
細胞内の位置 | Cytoplasm, cytosol : P14902 |
タンパク質・核酸の鎖数 | 4 |
化学式量合計 | 183870.15 |
構造登録者 | |
主引用文献 | Nelp, M.T.,Kates, P.A.,Hunt, J.T.,Newitt, J.A.,Balog, A.,Maley, D.,Zhu, X.,Abell, L.,Allentoff, A.,Borzilleri, R.,Lewis, H.A.,Lin, Z.,Seitz, S.P.,Yan, C.,Groves, J.T. Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form. Proc. Natl. Acad. Sci. U.S.A., 115:3249-3254, 2018 Cited by PubMed Abstract: For cancer cells to survive and proliferate, they must escape normal immune destruction. One mechanism by which this is accomplished is through immune suppression effected by up-regulation of indoleamine 2,3-dioxygenase (IDO1), a heme enzyme that catalyzes the oxidation of tryptophan to -formylkynurenine. On deformylation, kynurenine and downstream metabolites suppress T cell function. The importance of this immunosuppressive mechanism has spurred intense interest in the development of clinical IDO1 inhibitors. Herein, we describe the mechanism by which a class of compounds effectively and specifically inhibits IDO1 by targeting its apo-form. We show that the in vitro kinetics of inhibition coincide with an unusually high rate of intrinsic enzyme-heme dissociation, especially in the ferric form. X-ray crystal structures of the inhibitor-enzyme complexes show that heme is displaced from the enzyme and blocked from rebinding by these compounds. The results reveal that apo-IDO1 serves as a unique target for inhibition and that heme lability plays an important role in posttranslational regulation. PubMed: 29531094DOI: 10.1073/pnas.1719190115 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.822 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード